title: Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.
abstract: Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR.
authors.affiliation: Inserm CIC 0802, University Hospital, Poitiers, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Millot
authors.forename: Alexander
authors.initials: A
authors.lastname: Claviez
authors.forename: Guy
authors.initials: G
authors.lastname: Leverger
authors.forename: Selim
authors.initials: S
authors.lastname: Corbaciglu
authors.forename: Andreas H
authors.initials: AH
authors.lastname: Groll
authors.forename: Meinolf
authors.initials: M
authors.lastname: Suttorp
mesh_terms: D000293:Adolescent; D000328:Adult; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D015996:Survival Rate; D028761:Withholding Treatment; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: children; chronic myeloid leukemia; complete molecular response; imatinib